MiNK Therapeutics Partners with C-Further to Develop Pediatric Cancer Therapy
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 10 2026
0mins
Should l Buy INKT?
Source: Newsfilter
- Strategic Collaboration Initiated: MiNK Therapeutics has partnered with C-Further, securing approximately $1.1 million in non-dilutive funding to advance a PRAME-targeted TCR-engineered iNKT cell therapy, reflecting a shared commitment to improving treatment options for pediatric cancers.
- Platform Advantages: This collaboration leverages MiNK's iNKT cell platform to precisely target the PRAME antigen, aiming to overcome limitations of traditional cell therapies by providing an off-the-shelf solution without HLA matching, thereby accelerating treatment and enhancing tolerability, particularly for children with aggressive cancers.
- Clinical Candidate Evaluation: Researchers from the University of Southampton will support independent comparative preclinical studies to assess the anti-tumor activity and safety of the therapy across various pediatric cancer models, ensuring the selection of the most suitable clinical candidate for advancement to first-in-human trials.
- Commercial Potential Outlook: The agreement includes a significant double-digit share of downstream commercial revenues, underscoring the importance of MiNK's iNKT platform in next-generation TCR-based cellular therapies, which is expected to generate substantial long-term revenue for the company.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy INKT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on INKT
Wall Street analysts forecast INKT stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 10.520
Low
35.00
Averages
35.00
High
35.00
Current: 10.520
Low
35.00
Averages
35.00
High
35.00
About INKT
MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. It is advancing a pipeline of both native and engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. Its advanced product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy designed to provide transformative treatment options. AgenT-797 is an iNKT cell therapy that harnesses the dual power of innate and adaptive immunity. In addition, it is advancing a pipeline of allogeneic, engineered iNKT programs. Its two advanced preclinical engineered programs are MiNK-413, an IL-15 armored CAR-iNKT program targeting B cell maturation antigen (BCMA), and MiNK-215, an IL-15 armored tumor stromal targeting FAP-CAR-iNKT program.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
MiNK Therapeutics Q4 Earnings Beat Expectations
- Earnings Performance: MiNK Therapeutics reported a Q4 GAAP EPS of -$0.56, beating expectations by $0.12, indicating improved financial management that may bolster investor confidence.
- Cash Position: The company ended 2025 with a cash balance of $13.4 million, demonstrating its ability to maintain liquidity in operations, which is crucial for supporting future R&D and operational activities.
- Funding Progress: Through an at-the-market sales agreement, MiNK raised an additional $3.0 million by year-end, providing a runway through 2026 and enhancing its financial stability.
- Stock Price Reaction: Following the announcement of a collaboration with C-Further for pediatric cancer treatments, MiNK Therapeutics' stock surged 60%, reflecting market optimism regarding its future growth potential.
See More
MiNK Therapeutics Financial and Clinical Progress Update
- Cash Flow Improvement: MiNK Therapeutics increased its cash balance to $13.4 million from $4.6 million, despite reporting a net loss of $12.5 million for 2025, indicating some effectiveness in financial management while still facing ongoing financial pressures.
- Clinical Trial Progress: The company has advanced its allogeneic invariant natural killer T cell platform into Phase 2 clinical trials for solid tumors and autoimmune inflammatory conditions, demonstrating durable survival and complete remission in heavily pretreated cancer patients, although uncertainties in clinical development remain.
- Significant Cost Control: Operating costs decreased by nearly 40% year-over-year, which not only enhances capital efficiency but also provides more funding support for future clinical trials and R&D, despite potential clinical and regulatory risks that need to be monitored.
- External Funding Support: The company raised an additional $3 million post-year-end through an at-the-market facility, further strengthening its financial position to support clinical trials in graft versus host disease and gastric cancer, with results expected to be presented at a major conference in the first half of the year.
See More
MiNK Therapeutics Q4 2025 Earnings Call Insights
- Clinical Activity Performance: MiNK Therapeutics reported in Q4 2025 that patients in its solid tumor program, when combined with PD-1 therapies, achieved a median overall survival exceeding 23 months and complete remissions lasting over 2 years, demonstrating the clinical efficacy and safety of its iNKT platform, which could enhance future market recognition.
- Improved Financial Position: CFO Melissa Orilall reported a cash balance of $13.4 million in Q4 2025, significantly up from $4.6 million year-over-year, and raised an additional $3 million through market financing, ensuring operational funding through 2026 to support key clinical milestones.
- Clinical Trial Progress: The company plans to initiate the first patient dosing in its randomized Phase II study for ARDS at top centers in Ukraine and the U.S., with initial clinical data expected in the second half of this year, indicating positive advancements in addressing acute respiratory distress syndrome.
- Strategic Investment Focus: Management emphasized non-dilutive funding and partnerships as a core operational model, particularly for the GvHD study, having secured external funding to advance MiNK cells into clinical trials, reflecting the company's commitment to future market opportunities.
See More
MiNK Therapeutics Announces 2026 Clinical Trial Plans
- Clinical Trial Initiation: MiNK Therapeutics plans to initiate Phase 2 trials for ARDS and hypoxemic pneumonia in 1H 2026, targeting a market opportunity of approximately 200,000 to 300,000 patients annually in the US and EU, indicating significant commercial potential.
- Enhanced Funding Support: The collaboration with the C-Further Consortium provides MiNK with up to $1.1 million in non-dilutive funding, which not only supports the development of PRAME-TCR iNKT in pediatric oncology but also strengthens the company's financial stability.
- GVHD Program Advancement: With NIH STTR grant and Mary Gooze philanthropic award backing, MiNK's GVHD clinical trial is expected to begin first dosing in May 2026, showcasing the company's strong potential in the transplantation field.
- Improved Financial Position: As of December 31, 2025, MiNK reported a cash balance of $13.36 million, significantly up from 2024, with a net loss of $12.49 million for the year, reflecting ongoing improvements in financial management and operational efficiency.
See More
MiNK Therapeutics Secures $1.1 Million Funding for Pediatric Cancer Collaboration
- Funding Support: MiNK Therapeutics has secured approximately $1.1 million in non-dilutive funding to support the development of its PRAME-TCR-iNKT asset, which will significantly advance its efforts in pediatric cancer treatment.
- Revenue Sharing Agreement: The collaboration includes a double-digit share of downstream commercial revenues, which not only provides MiNK with a continuous income stream but also enhances its competitive position in the market.
- Innovative Treatment Platform: MiNK's iNKT cell therapy, as an allogeneic, off-the-shelf treatment, can be manufactured in advance and cryopreserved, ensuring timely access for patients without the need for HLA matching or toxic lymphodepleting chemotherapy.
- Clinical Data Validation: The clinical data published by MiNK in July 2025 indicates that a patient with metastatic testicular cancer achieved complete and durable remission following treatment with its iNKT cell therapy, demonstrating the therapy's efficacy and safety, thereby solidifying its position in the biopharmaceutical sector.
See More
MiNK Therapeutics Partners with C-Further for Pediatric Oncology
- Stock Surge: MiNK Therapeutics Inc. (INKT) shares soared by 73% in pre-market trading following the announcement of a strategic collaboration with C-Further, indicating strong market confidence in its iNKT cell therapy.
- Innovative Therapy Development: The collaboration aims to develop a TCR-engineered iNKT cell therapy targeting PRAME, an antigen relevant in various pediatric and adult cancers, particularly in pediatric sarcomas and acute myeloid leukemia, addressing critical treatment gaps.
- Funding and Commercial Terms: Under the agreement, MiNK will receive approximately $1.1 million in non-dilutive funding for IND development, with milestone payments based on scientific progress, and a double-digit share of downstream commercial revenues, highlighting the value of its proprietary platform.
- Clinical Research and Future Outlook: Investigators at the University of Southampton will lead comparative preclinical studies to nominate a lead candidate for first-in-human trials in children, with MiNK's CEO emphasizing the collaboration's validation of its iNKT platform's maturity and potential in pediatric oncology.
See More
MiNK Therapeutics Q4 Earnings Beat Expectations
- Earnings Performance: MiNK Therapeutics reported a Q4 GAAP EPS of -$0.56, beating expectations by $0.12, indicating improved financial management that may bolster investor confidence.
- Cash Position: The company ended 2025 with a cash balance of $13.4 million, demonstrating its ability to maintain liquidity in operations, which is crucial for supporting future R&D and operational activities.
- Funding Progress: Through an at-the-market sales agreement, MiNK raised an additional $3.0 million by year-end, providing a runway through 2026 and enhancing its financial stability.
- Stock Price Reaction: Following the announcement of a collaboration with C-Further for pediatric cancer treatments, MiNK Therapeutics' stock surged 60%, reflecting market optimism regarding its future growth potential.
See More
MiNK Therapeutics Financial and Clinical Progress Update
- Cash Flow Improvement: MiNK Therapeutics increased its cash balance to $13.4 million from $4.6 million, despite reporting a net loss of $12.5 million for 2025, indicating some effectiveness in financial management while still facing ongoing financial pressures.
- Clinical Trial Progress: The company has advanced its allogeneic invariant natural killer T cell platform into Phase 2 clinical trials for solid tumors and autoimmune inflammatory conditions, demonstrating durable survival and complete remission in heavily pretreated cancer patients, although uncertainties in clinical development remain.
- Significant Cost Control: Operating costs decreased by nearly 40% year-over-year, which not only enhances capital efficiency but also provides more funding support for future clinical trials and R&D, despite potential clinical and regulatory risks that need to be monitored.
- External Funding Support: The company raised an additional $3 million post-year-end through an at-the-market facility, further strengthening its financial position to support clinical trials in graft versus host disease and gastric cancer, with results expected to be presented at a major conference in the first half of the year.
See More
MiNK Therapeutics Q4 2025 Earnings Call Insights
- Clinical Activity Performance: MiNK Therapeutics reported in Q4 2025 that patients in its solid tumor program, when combined with PD-1 therapies, achieved a median overall survival exceeding 23 months and complete remissions lasting over 2 years, demonstrating the clinical efficacy and safety of its iNKT platform, which could enhance future market recognition.
- Improved Financial Position: CFO Melissa Orilall reported a cash balance of $13.4 million in Q4 2025, significantly up from $4.6 million year-over-year, and raised an additional $3 million through market financing, ensuring operational funding through 2026 to support key clinical milestones.
- Clinical Trial Progress: The company plans to initiate the first patient dosing in its randomized Phase II study for ARDS at top centers in Ukraine and the U.S., with initial clinical data expected in the second half of this year, indicating positive advancements in addressing acute respiratory distress syndrome.
- Strategic Investment Focus: Management emphasized non-dilutive funding and partnerships as a core operational model, particularly for the GvHD study, having secured external funding to advance MiNK cells into clinical trials, reflecting the company's commitment to future market opportunities.
See More
MiNK Therapeutics Announces 2026 Clinical Trial Plans
- Clinical Trial Initiation: MiNK Therapeutics plans to initiate Phase 2 trials for ARDS and hypoxemic pneumonia in 1H 2026, targeting a market opportunity of approximately 200,000 to 300,000 patients annually in the US and EU, indicating significant commercial potential.
- Enhanced Funding Support: The collaboration with the C-Further Consortium provides MiNK with up to $1.1 million in non-dilutive funding, which not only supports the development of PRAME-TCR iNKT in pediatric oncology but also strengthens the company's financial stability.
- GVHD Program Advancement: With NIH STTR grant and Mary Gooze philanthropic award backing, MiNK's GVHD clinical trial is expected to begin first dosing in May 2026, showcasing the company's strong potential in the transplantation field.
- Improved Financial Position: As of December 31, 2025, MiNK reported a cash balance of $13.36 million, significantly up from 2024, with a net loss of $12.49 million for the year, reflecting ongoing improvements in financial management and operational efficiency.
See More
MiNK Therapeutics Secures $1.1 Million Funding for Pediatric Cancer Collaboration
- Funding Support: MiNK Therapeutics has secured approximately $1.1 million in non-dilutive funding to support the development of its PRAME-TCR-iNKT asset, which will significantly advance its efforts in pediatric cancer treatment.
- Revenue Sharing Agreement: The collaboration includes a double-digit share of downstream commercial revenues, which not only provides MiNK with a continuous income stream but also enhances its competitive position in the market.
- Innovative Treatment Platform: MiNK's iNKT cell therapy, as an allogeneic, off-the-shelf treatment, can be manufactured in advance and cryopreserved, ensuring timely access for patients without the need for HLA matching or toxic lymphodepleting chemotherapy.
- Clinical Data Validation: The clinical data published by MiNK in July 2025 indicates that a patient with metastatic testicular cancer achieved complete and durable remission following treatment with its iNKT cell therapy, demonstrating the therapy's efficacy and safety, thereby solidifying its position in the biopharmaceutical sector.
See More
MiNK Therapeutics Partners with C-Further for Pediatric Oncology
- Stock Surge: MiNK Therapeutics Inc. (INKT) shares soared by 73% in pre-market trading following the announcement of a strategic collaboration with C-Further, indicating strong market confidence in its iNKT cell therapy.
- Innovative Therapy Development: The collaboration aims to develop a TCR-engineered iNKT cell therapy targeting PRAME, an antigen relevant in various pediatric and adult cancers, particularly in pediatric sarcomas and acute myeloid leukemia, addressing critical treatment gaps.
- Funding and Commercial Terms: Under the agreement, MiNK will receive approximately $1.1 million in non-dilutive funding for IND development, with milestone payments based on scientific progress, and a double-digit share of downstream commercial revenues, highlighting the value of its proprietary platform.
- Clinical Research and Future Outlook: Investigators at the University of Southampton will lead comparative preclinical studies to nominate a lead candidate for first-in-human trials in children, with MiNK's CEO emphasizing the collaboration's validation of its iNKT platform's maturity and potential in pediatric oncology.
See More
